New Delhi, March 27 -- Bengaluru-based life sciences commercialisation firm Indegene sees significant headroom for growth in the US, its largest market, despite uncertainties around the new Trump regime's stance on regulatory and pricing issues. Top global pharma companies are doubling down on the use of technology and AI to make processes more agile, which plays to Indegene's strengths, CEO and co-founder Manish Gupta told Mint in an interview.

"A combination of ageing populations, rising incomes, and the fact that technology is at a stage where multiple options can be thrown in [means] this industry will continue to grow for a very long period of time," Gupta said.

A large chunk of Indegene's revenue (64% as of Q3FY25) comes from the ...